Cargando…
Privileged Scaffolds for Potent and Specific Inhibitors of Mono-ADP-Ribosylating PARPs
The identification of new targets to address unmet medical needs, better in a personalized way, is an urgent necessity. The introduction of PARP1 inhibitors into therapy, almost ten years ago, has represented a step forward this need being an innovate cancer treatment through a precision medicine ap...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420676/ https://www.ncbi.nlm.nih.gov/pubmed/37570820 http://dx.doi.org/10.3390/molecules28155849 |